Skip to main content
Gene Therapy Net RSS feed Follow Gene Therapy Net on Twitter LinkedIn - Gene Therapy Net discussion group Facebook - Gene Therapy Net

Newsletter July 2017

News: First gene therapy — 'a true living drug' — on the cusp of FDA approval
Food and Drug Administration advisers on Wednesday enthusiastically endorsed a first-of-its-kind cancer treatment that uses patients' revved-up immune cells to fight the disease, concluding that the therapy's benefits for desperately ill children far outweigh its potentially dangerous side effects. The unanimous recommendation from the Oncologic Drugs Advisory Committee means the treatment could be approved by the FDA by the end of September, forging a new path in the immunotherapy frontier.

News: South Korea approves first gene therapy drug
South Korea's health authorities said Wednesday that they have approved the use of the country's first gene therapy drug to help patients with degenerative joint disease. The drug, Invossa, manufactured by local drug firm Kolon Life Science Inc. has obtained the green light from the Ministry of Food and Drug Safety for sales in the domestic market. Invossa is the world's first cell-medicated gene therapy for osteoarthritis, a disorder involving movable joints. The company said the drug can be injected into the joint cavity of a patient. The drug has proven to reduce osteoarthritis pain and improve cartilage through clinical trials, said Kolon Life Science, expecting to help an estimated five million patients in the country.

News: Gene Therapy & Mesothelioma
Technological innovations are changing the world we live in every day, including the way society views diseases that have been around for hundreds of years. Cancer continues to be a leading cause of death around the world, but day by day we, as a society, are getting closer to finding a cure. In 2016, former President Barack Obama asked former Vice President Joe Biden to head the Cancer Moonshot Initiative (CMI), whose overarching goal would be to find a cure for cancer by the year 2020. In the time that’s passed, Biden has formed a committee of governmental organizations and a Blue Ribbon Panel that provided recommendations of how to achieve the lofty goals, and set to bringing this moonshot into reality.

Report: Gene Therapy Market by Technology, Opportunity Analysis and Industry Forecasts, 2017 – 2022
Gene Therapy Market Report gives an expository assessment of the prime difficulties confronted by this Market currently and in the coming years, which helps investors in understanding the difficulties they may confront while working in this Marketplace over a forecast period. In this report, the value of Gene Therapy Market in 2016 and expected value by 2022, as well as development in the vicinity of 2016 and 2022 are covered. Different Gene Therapy industry driving players are contemplated with respect to their company profile, product portfolio, value, cost capacity, income and growth.
The top market players which are included in the Gene Therapy Market report are Bluebird Bio, Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical Inc., Advantagene….and others

Get a Sample of Gene Therapy Market research report...

Conference: Gene Therapy Bioproduction Conference
CHI's Gene Therapy CMC, Analytics and Bioproduction Week (August 23-25, 2017, Boston, MA) addresses the latest CMC and analytical challenges, plus developments in clinical and commercial gene therapy production, process development, formulation, analysis and quality control with over 25+ case studies from leading institutes and market leaders such as GSK, Dimension Therapeutics, Voyager, Shire, Sanofi, Uniqure, Bluebird Bio, Biogen and Editas.
Gene Therapy CMC and Analytics, Part One of the stream and new for 2017, examines building an effective, regulatory-compliant CMC development strategy for vector-based gene therapies followed by in-depth sessions on potency assay qualification and validation, characterization, stability, comparability and quality control.
Part two, Gene Therapy Bioproduction, focuses on the challenges involved in large-scale AAV and lentivirus process development and manufacturing, supported by dedicated sessions on process validation, product lifecycle management, formulation and industrialization with in depth case studies from such as Uniqure, Voyager, Bluebird, Dimension Therapeutics. Join the industry’s most dedicated gene therapy production meeting this August in Boston, part of The Bioprocessing Summit.


- 20 - 22 July 2017, The 23th Annual Meeting of the Japan Society of Gene Therapy (JSGT), Okayama City, Japan
- 24 - 25 August 2017, Gene Therapy Bioproduction Conference, Boston, MA
- 31 August - 1 September 2017, 2nd International Conference on Nucleic Acids, Molecular Biology & Biologics Conference, Philadelphia, PA
- 11 - 13 September 2017, Manufacturing Cell and Gene Therapy Products, London,UK
- 19 - 21 September 2017, 3rd Annual Phacilitate Cell & Gene Therapy Europe, Berlin, Germany
- 25 - 28 September 2017, Cell & Gene Therapy Bioprocessing & Commercialization, Boston, MA
- 27 - 28 September 2017, Annual Summit on Cell Therapy and Molecular Medicine, Chicago, Il
- 17 – 20 October 2017, XXV Congress of the European Society of Gene and Cell Therapy (ESGCT), Berlin, Germany
- 18 – 19 October 2017, Market Access for Cell and Gene Therapies Congress, London, UK
- 9 - 10 November 2017, 3rd Annual Genome Editing Congress, London, UK
- 9 - 10 November 2017, 3rd Annual Cell & Gene Therapy Congress, London, UK
- 13 - 15 November 2017, World Orphan Drug Congress, Barcelona, Spain
- 15 - 17 November 2017, 16th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases, Sonoma, California
- 23 - 25 January 2018, Cell & Gene Therapy World event 2018, Miami, Fl
- 15 March 2018, British Society for Gene and Cell Therapy (BSGCT) Public Engagement 2018, Oxford, UK
- 15 - 17 March 2018, 7th International Conference and Exhibition on Cell and Gene Therapy, London, UK
- 27 April 2018, Annual conference of the British Society for Gene and Cell Therapy (BSGCT), Cardiff, Wales, UK
- 16 - 19 May 2018, American Society of Gene and Cell Therapy (ASGCT) 21th Annual Meeting, Chicago, IL


Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines. Other information websites created and maintained by the owner of Gene Therapy Net are Dengue Virus Net, Influenza Virus Net, Ebola Virus Net, Chikungunya Virus Net and Zika Virus Net.
To unsubscribe from the Newsletter, please login and edit your subscription details, or {unsubscribe}unsubscribe direct{/unsubscribe}, or contact us. You are currently registered as: {subtag:name}, email address: {subtag:email}.

Advertise on this site?